-
Mashup Score: 9Real-World Database Studies in Oncology: A Call for Standards - 1 month(s) ago
Real-world data (RWD), the data relating to patient health status and routinely collected in the delivery of health care, can provide critical evidence about care and outcomes across the cancer continuum. When analyzed using rigorous methods, RWD can address a number of important questions that are not practical, feasible, or ethical to address with clinical trials. This important advantage of RWD is also a limitation, namely, what is captured in real-world databases reflects the observed experiences,
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10
Advancements in comprehending the biogenesis, dependencies, and mutational landscape of multiple myeloma dramatically expanded over the past two decades. This knowledge progress was paralleled by similar surge in novel therapeutics discovery, including the unveiling of new targets and classes of drugs. These advancements presented us, however, with novel challenges to prognosticate the disease with greater precision accounting for its individual biologic, genomic, and therapeutic features. In the article
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Excellent editorial by Paola Neri, Holly Lee and @NBahlis, šš»Artificial Intelligence Individualized Risk Classifier in Multiple Myeloma | Journal of Clinical Oncology #mmsm @JCO_ASCO https://t.co/oOcquWMqyf
-
-
Mashup Score: 8
Advancements in comprehending the biogenesis, dependencies, and mutational landscape of multiple myeloma dramatically expanded over the past two decades. This knowledge progress was paralleled by similar surge in novel therapeutics discovery, including the unveiling of new targets and classes of drugs. These advancements presented us, however, with novel challenges to prognosticate the disease with greater precision accounting for its individual biologic, genomic, and therapeutic features. In the article
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @NBahlis: Our editorial with Dr Paola Neri, @hollyleeYJā© out in JCO today https://t.co/HzD8WzVwLm commenting on the very elegant work ofā¦
-
-
Mashup Score: 8
Advancements in comprehending the biogenesis, dependencies, and mutational landscape of multiple myeloma dramatically expanded over the past two decades. This knowledge progress was paralleled by similar surge in novel therapeutics discovery, including the unveiling of new targets and classes of drugs. These advancements presented us, however, with novel challenges to prognosticate the disease with greater precision accounting for its individual biologic, genomic, and therapeutic features. In the article
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @NBahlis: Our editorial with Dr Paola Neri, @hollyleeYJā© out in JCO today https://t.co/HzD8WzVwLm commenting on the very elegant work ofā¦
-
-
Mashup Score: 22
PURPOSE Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T. PATIENTS AND METHODS This is an international retrospective observational study including patients with RRMM infused with currently available commercial or academically produced antiāB-cell maturation antigen (BCMA) CAR-T. We describe characteristics and outcomes in Europe (n = 136) and the United States (n = 133). Independent predictors of relapse/progression built a simple prediction model (Myeloma CAR-T Relapse [MyCARe] model) in the training cohort (Europe), which was externally validated (US cohort) and tested within patient- and treatment-specific subgroups. RESULTS The overall response rate was 87% and comparable between both cohorts, and complete responses were seen in 48% (Europe) and 49% (the United States). The median time to r
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
MyCARe Scoring by @NicoGagelmann et al. in @JCO_ASCO provides prognostic utility for different CAR-T products and is based on real-life data to identify myeloma patients benefiting from BCMA-CAR-T #mmsm @NausheenAhmedMD @Abdallah81MD https://t.co/VP9rKZO7mF
-
-
Mashup Score: 11Immunotherapies for Alzheimerās disease - 4 month(s) ago
Antibodies targeting amyloid-Ī² aggregates slow decline in Alzheimerās disease
Source: www.science.orgCategories: General Medicine News, Hem/OncsTweet-
RT @LabWaggoner: Antibodies targeting amyloid-Ī² aggregates slow decline in Alzheimerās disease @ScienceMagazine https://t.co/R2JRva9tB9
-
-
Mashup Score: 11Immunotherapies for Alzheimerās disease - 5 month(s) ago
Antibodies targeting amyloid-Ī² aggregates slow decline in Alzheimerās disease
Source: www.science.orgCategories: General Medicine News, Hem/OncsTweet-
RT @LabWaggoner: Antibodies targeting amyloid-Ī² aggregates slow decline in Alzheimerās disease @ScienceMagazine https://t.co/R2JRva9tB9
-
-
Mashup Score: 1GlĆ¼cksklee, the Quad, and High-Risk Myeloma - 7 month(s) ago
In the article that accompanies this editorial, Leypoldt et al 1 describe the results of a forward-thinking study focused on the management of high-risk newly diagnosed multiple myeloma (HR NDMM) using the quadruplet (quad) regimen: isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd). This multicenter, phase II trial enrolled patients with HR NDMM, cytogenetically defined as the presence of del17p, t(4;14), t(14;16), or more than three copies of 1q21. Patients were not eligible if they had
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
šExcellent Editorial in @JCO_ASCO by @AjayNookaMD @JKaufmanMD and @SagarLonialMD on the GMMG-CONCEPT trial for High Risk Myeloma #mmsm GlĆ¼cksklee, the Quad, and High-Risk Myeloma https://t.co/H4UvCkUAjn
-
-
Mashup Score: 17Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial - 7 month(s) ago
Key Points. The VITAL study of birtamimab in all stages of newly diagnosed ALĀ amyloidosis was discontinued early per futility analysis.Birtamimab improved post
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
š @MorieGertz et al šAnti-amloid mAb Birtamimab improved all-cause mortality in Mayo stage IV AL amyloidosis with cardiac involvement šBirtamimab plus standard of care in light-chain amyloidosis: Phase 3 randomized placebo-controlled VITAL trial https://t.co/hRCZVmV1qb https://t.co/N7mNuKSEw5
-
-
Mashup Score: 2
Original Article from The New England Journal of Medicine ā Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
Source: www.nejm.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @EagleMyeloma: I was skeptical, but these PFS curves from CARTITUDE-1 and CARTITUDE-4 do seem different #mmsm https://t.co/sU2g2CdxG7 hā¦
-
Real-World Database Studies in Oncology: A Call for Standards in @JCO_ASCO will give guidance on the conduct and reporting of RWD in JCO including quality standards https://t.co/VLDdjzdLl0